Quarterly report pursuant to Section 13 or 15(d)

Net Loss per Share Attributable to Common Stock - Schedule of Outstanding Shares of Common Stock Equivalents (Details)

v3.24.3
Net Loss per Share Attributable to Common Stock - Schedule of Outstanding Shares of Common Stock Equivalents (Details) - shares
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Stock options        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Common stock equivalents (in shares) 147,707 147,707 147,707 147,707
Non-vested restricted stock awards        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Common stock equivalents (in shares) 826,315 1,981,597 826,315 1,981,597
Non-vested restricted stock units        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Common stock equivalents (in shares) 2,777,715 1,977,986 2,777,715 1,977,986
Common stock warrants        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Common stock equivalents (in shares) 240,100 240,100 240,100 240,100
Convertible debt        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Common stock equivalents (in shares) 1,759,804 583,333 1,759,804 583,333